Anti-Human HLA-DR10 (DRB1*1001) Antibody (SAA0175), PE

Catalog No.

FHM02312

Species reactivity

Human

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Conjugation

PE

Concentration

0.5 mg/ml

Endotoxin level

Please contact with the lab for this information.

Applications

FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.

Stability and Storage

Store at 4°C for 12 months. Protect from light. Do not freeze.

Clone ID

SAA0175

Adaptable antibody Nanoworms designed for non-Hodgkin lymphoma., PMID:32916604

The small molecule antibody mimic SH7139 targets a family of HLA-DRs expressed by B-cell lymphomas and other solid cancers., PMID:32588667

Neuromyelitis Optica (NMO IgG+) and Genetic Susceptibility, Potential Ethnic Influences., PMID:26923907

Reinfection of cytomegalovirus in renal transplantation., PMID:21701077

A selective high affinity ligand (SHAL) designed to bind to an over-expressed human antigen on non-Hodgkin's lymphoma also binds to canine B-cell lymphomas., PMID:20576295

Association between antibody response against cytomegalovirus strain-specific glycoprotein H epitopes and HLA-DR., PMID:19563400

Hexa-arginine enhanced uptake and residualization of selective high affinity ligands by Raji lymphoma cells., PMID:19383174

Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia., PMID:19148487

Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imaging., PMID:20443696

Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: initial application to lymphoma/leukemia., PMID:17875798

Recombinant expression of the beta-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules., PMID:17803448

Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma., PMID:17786303

Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors., PMID:17651040

Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma., PMID:17631545

Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemia., PMID:17373772

Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells., PMID:17257080

Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics., PMID:10541366

Lichenoid erythrodermic bullous pemphigoid of the African patient., PMID:9810884

Influence of the QKRAA/QRRAA/RRRAA motifs of the third hypervariable region of HLA-DRB1 in the development of rheumatoid arthritis., PMID:9002048

Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10., PMID:8917632

Shared epitopes of the HLA-DR10 molecule recognized by murine and human mAbs., PMID:7684257

Document Download

Anti-Human HLA-DR10 (DRB1*1001) Antibody (SAA0175), PE.pdf